Fusion Net Income vs Research Development Analysis
| FUSN Stock | USD 21.55 0.03 0.14% |
Fusion Pharmaceuticals financial indicator trend analysis is much more than just examining Fusion Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fusion Pharmaceuticals is a good investment. Please check the relationship between Fusion Pharmaceuticals Net Income and its Research Development accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharmaceuticals guide.
Net Income vs Research Development
Net Income vs Research Development Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fusion Pharmaceuticals Net Income account and Research Development. At this time, the significance of the direction appears to have pay attention.
The correlation between Fusion Pharmaceuticals' Net Income and Research Development is -0.9. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Research Development in the same time period over historical financial statements of Fusion Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Fusion Pharmaceuticals' Net Income and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Fusion Pharmaceuticals are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Net Income i.e., Fusion Pharmaceuticals' Net Income and Research Development go up and down completely randomly.
Correlation Coefficient | -0.9 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Fusion Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Fusion Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Research Development
Most indicators from Fusion Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fusion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharmaceuticals guide.At this time, Fusion Pharmaceuticals' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 4th of June 2024, Enterprise Value is likely to grow to about 649.9 M, though Tax Provision is likely to grow to (806.5 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 634K | 909K | 1.2M | 1.3M | Total Operating Expenses | 83.5M | 89.5M | 100.0M | 54.3M |
Fusion Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Fusion Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fusion Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Common Stock Shares Outstanding | 155.7M | 22.0M | 42.6M | 43.7M | 65.6M | 57.7M | |
| Total Assets | 69.4M | 310.7M | 252.3M | 219.1M | 285.8M | 214.3M | |
| Other Current Liab | 3.4M | 7.5M | 7.6M | 10.0M | 9.9M | 7.3M | |
| Total Current Liabilities | 4.3M | 11.9M | 12.5M | 15.1M | 16.2M | 11.3M | |
| Total Stockholder Equity | (33.5M) | 294.5M | 231.5M | 162.2M | 222.5M | 157.5M | |
| Other Liab | 321K | 4.3M | 2.8M | 3.0M | 3.4M | 2.3M | |
| Net Tangible Assets | (33.5M) | 294.5M | 231.5M | 162.2M | 186.6M | 140.1M | |
| Property Plant And Equipment Net | 1.3M | 2.0M | 9.5M | 10.3M | 23.9M | 25.1M | |
| Net Debt | (59.6M) | (90.5M) | (46.2M) | (3.6M) | (11.6M) | (12.2M) | |
| Retained Earnings | (34.8M) | (113.2M) | (194.3M) | (281.9M) | (376.8M) | (357.9M) | |
| Accounts Payable | 830K | 3.4M | 2.2M | 2.7M | 1.9M | 2.1M | |
| Cash | 65.3M | 90.5M | 52.9M | 43.9M | 61.9M | 62.9M | |
| Non Current Assets Total | 2.8M | 82.5M | 40.5M | 40.1M | 42.4M | 38.4M | |
| Non Currrent Assets Other | 1.5M | 2.8M | 9.4M | 9.2M | 849K | 806.6K | |
| Other Assets | 1.6M | 80.5M | 11.1M | 14.0M | 16.1M | 23.6M | |
| Cash And Short Term Investments | 65.3M | 222.4M | 200.8M | 186.6M | 234.1M | 172.0M | |
| Net Receivables | 428K | 794K | 357K | 1.7M | 4.2M | 4.4M | |
| Liabilities And Stockholders Equity | 69.4M | 310.7M | 252.3M | 219.1M | 285.8M | 214.3M | |
| Non Current Liabilities Total | 98.6M | 4.3M | 8.3M | 41.8M | 47.1M | 33.0M | |
| Capital Surpluse | 1.3M | 407.7M | 425.8M | 444.6M | 511.2M | 281.6M | |
| Inventory | 503K | 4.2M | 10.4M | (9.9M) | (8.9M) | (8.4M) | |
| Other Current Assets | 278K | 727K | 233K | 509K | 5.1M | 5.4M | |
| Other Stockholder Equity | (70.3M) | 407.7M | 425.8M | 444.6M | 599.0M | 331.4M | |
| Total Liab | 102.9M | 16.2M | 20.8M | 56.8M | 63.4M | 41.2M | |
| Net Invested Capital | (33.5M) | 294.5M | 231.5M | 196.5M | 257.3M | 170.2M | |
| Property Plant And Equipment Gross | 1.3M | 2.0M | 9.5M | 12.3M | 26.4M | 27.7M | |
| Total Current Assets | 66.6M | 228.2M | 211.8M | 179.0M | 243.4M | 175.8M | |
| Accumulated Other Comprehensive Income | (428K) | 44K | (115K) | (469K) | 237K | 248.9K | |
| Net Working Capital | 62.3M | 216.3M | 199.3M | 163.9M | 227.2M | 164.6M | |
| Property Plant Equipment | 1.3M | 2.0M | 3.0M | 4.6M | 5.3M | 5.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Fusion Stock
When determining whether Fusion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fusion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fusion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fusion Pharmaceuticals Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharmaceuticals. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Revenue Per Share 0.028 | Quarterly Revenue Growth (1.00) | Return On Assets (0.23) | Return On Equity (0.47) |
The market value of Fusion Pharmaceuticals is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fusion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.